| AMG 102 + bevacizumab |
HGF/SF + VEGF |
II |
NCT01113398 |
36 |
02/2016 |
Sanofi |
|
| AMG 386 |
Ang 1/2 |
II |
NCT01290263 |
86 |
12/2016 |
Dana-Farber Cancer Institute |
|
| AMG 386 + bevacizumab |
Ang 1/2 + VEGF |
II |
NCT01609790 |
141 |
07/2015 |
National Cancer Institute |
|
| AMG 595 |
EGFRvIII |
I |
NCT01475006 |
60 |
10/2015 |
Amgen |
|
| APG101 + radiation therapy |
CD95 |
II |
NCT01071837 |
83 |
06/2015 |
Apogenix GmbH |
|
| Axitinib |
VEGFR/PDGF |
II |
NCT01562197 |
52 |
05/2016 |
Bart Neyns |
|
| BKM120 |
PI3K |
II |
NCT01339052 |
65 |
04/2015 |
Dana-Farber Cancer Institute |
|
| BKM120 + bevacizumab |
PI3K + VEGF |
I/II |
NCT01349660 |
93 |
12/2016 |
SCRI Development Innovations, LLC |
|
| BKM120 + carboplatin vs BKM120 + lomustine |
PI3K |
I/II |
NCT01934361 |
176 |
03/2017 |
Novartis Pharmaceuticals |
|
| BKM120 + LDE225 |
PI3K + Hh |
I |
NCT01576666 |
118 |
04/2015 |
Novartis Pharmaceuticals |
|
| BKM120 + INC280 |
PI3K + c-Met |
I/II |
NCT01870726 |
74 |
08/2015 |
Novartis Pharmaceuticals |
|
| BGJ398 |
pan-FGFR |
II |
NCT01975701 |
34 |
05/2016 |
Novartis Pharmaceuticals |
|
| BIBW2992 + temozolomide |
HER2/EGFR |
I/II |
NCT00727506 |
151 |
03/2015 |
Boehringer Ingelheim |
|
| Bortezomib + bevacizumab + temozolomide |
26S proteasome |
I |
NCT01435395 |
18 |
12/2015 |
Emory University |
|
| Bevacizumab + dasatinib |
VEGF + Src |
I/II |
NCT00892177 |
183 |
11/2014 |
Alliance for Clinical Trials in Oncology |
|
| Cediranib + lomustine |
pan-VEGFR |
III |
NCT00777153 |
423 |
12/2014 |
AstraZeneca |
|
| Crizotinib |
ALK/ROS1 |
I/II |
NCT00939770 |
’96 |
12/2014 |
Children's Oncology Group |
|
| Dacomitinib |
pan-HER |
II |
NCT01520870 |
64 |
07/2015 |
Grupo Español de Investigación en Neurooncología |
|
| Dacomitinib |
pan-HER |
II |
NCT01112527 |
56 |
12/2014 |
Massachusetts General Hospital |
|
| Dasatinib + bevacizumab |
Src + VEGF |
II |
NCT00892177 |
183 |
11/2014 |
National Cancer Institute |
|
| Dovitinib |
FGFR |
II |
NCT01753713 |
55 |
12/2014 |
Case Comprehensive Cancer Center |
|
| Erlotinib |
EGFR |
N/A |
NCT01257594 |
22 |
12/2014 |
Columbia University |
|
| GDC-0084 |
PI3K |
I |
NCT01547546 |
68 |
08/2016 |
Genentech |
|
| Indoximod + temozolomide |
IDO |
I/II |
NCT02052648 |
18 |
03/2015 |
NewLink Genetics Corporation |
|
| INK128 |
mTORC 1/2 |
Pilot |
NCT02133183 |
40 |
12/2015 |
National Cancer Institute |
|
| INK128 + bevacizumab |
mTORC 1/2 + VEGF |
I |
NCT02142803 |
58 |
11/2014 |
National Cancer Institute |
|
| Lonafarnib + temozolomide |
FPTase |
I |
NCT00102648 |
35 |
12/2015 |
MD Anderson Cancer Center |
|
| LY2157299 + lomustine vs lomustine |
HGF/SF |
II |
NCT01582269 |
180 |
12/2014 |
Eli Lilly and Company |
|
| Macitentan + temozolomide |
ET-1 |
I |
NCT01499251 |
48 |
12/2014 |
Actelion |
|
| MK-1775 + temozolomide |
WEE1 |
I |
NCT01849146 |
114 |
12/2014 |
National Cancer Institute |
|
| Pazopanib + topotecan |
c-Kit/VEGF/PDGFR |
II |
NCT01931098 |
66 |
11/2020 |
MD Anderson Cancer Center |
|
| PF-00299804 |
pan-ERBB |
II |
NCT01112527 |
56 |
12/2014 |
Massachusetts General Hospital |
|
| Olaparib + temozolomide |
PARP |
I |
NCT01390571 |
34 |
09/2015 |
Cancer Research UK |
|
| Onartuzumab + bevacizumab vs onartuzumab vs bevacizumab |
c-Met + VEGF |
II |
NCT01632228 |
135 |
03/2015 |
Hoffmann-La Roche |
|
| Ridaforolimus + MK-2206 or Ridaforolimus + MK-0752 |
mTOR + Akt or mTOR + Notch |
I |
NCT01295632 |
124 |
12/2014 |
Merck Sharp & Dohme Corp. |
|
| RO4929097 + cediranib |
Notch |
I |
NCT01131234 |
50 |
09/2014 |
National Cancer Institute |
|
| Selinexor |
Exportin 1 (XPO1/CRM1) |
II |
NCT01986348 |
30 |
08/2015 |
Karyopharm Therapeutics, Inc |
|
| Sorafenib + everolimus |
VEGFR/Raf1 + mTOR |
I/II |
NCT01434602 |
118 |
10/2018 |
MD Anderson Cancer Center |
|
| Sorafenib + valproic acid + sildenafil |
VEGFR/Raf1 |
II |
NCT01817751 |
66 |
12/2017 |
Virginia Commonwealth University |
|
| Tivozanib |
VEGF |
II |
NCT01846871 |
21 |
06/2015 |
Massachusetts General Hospital |
|
| TRC105 + bevacizumab |
Endoglin (CD105) + VEGF |
II |
NCT01564914 |
22 |
06/2015 |
Tracon Pharmaceuticals Inc. |
|
| TRC105 + bevacizumab vs bevacizumab |
Endoglin (CD105) + VEGF |
I/II |
NCT01648348 |
128 |
12/2014 |
National Cancer Institute |
|
| Vandetanib + carboplatin vs Vandetanib → carboplatin |
VEGFR/EGFR |
II |
NCT00995007 |
112 |
07/2016 |
National Cancer Institute |
|
| Vandetanib + bevacizumab vs Bevacizumab |
VEGFR/EGFR + VEGF |
I/II |
NCT01266031 |
108 |
07/2016 |
MD Anderson Cancer Center |
|
| Vorinostat + bevacizumab |
HDAC + VEGF |
II |
NCT01738646 |
40 |
12/2015 |
Duke University |
|
| Vorinostat + isotretinoin + temozolomide |
HDAC |
I/II |
NCT00555399 |
189 |
11/2015 |
MD Anderson Cancer Center |
|
| Vorinostat + radiation therapy |
HDAC |
I |
NCT01378481 |
30 |
07/2016 |
National Cancer Institute |
